 |
|
|
| |
GARNET: High SVR Rates Following 8-Week Treatment
With Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir in
Patients With HCV Genotype 1b Infection
|
| |
| |
Reported by Jules Levin
26th Conference of the Asian Pacifi c Associati on for the Study of the Liver (APASL), 15Ð19 February 2017, Shanghai, China
Tania M Welzel1, Stefan Zeuzem1, Emily O Dumas2, Tarik Asselah3, David Shaw4, Rawi Hazzan5,
Xavier Forns6, Tami Pilot-Mati as3, Wenjing Lu3, Daniel E Cohen3, Jordan Feld7
1JW Goethe University, Frankfurt, Germany; 2AbbVie Inc., North Chicago, Illinois, United States; 3Centre de Recherche sur l'Inflammation, Inserm UMR 1149, Universite Paris Diderot, AP-HP Hopital Beaujon, Clichy, France; 4Royal Adelaide Hospital, Adelaide, South Australia, Australia; 5Ha'emek Medical Center, Afula, Israel; 6Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, Barcelona, Spain; 7Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada
|
| |
|
|
|
|
|
